Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type

The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Dhafiri, Mahdi, Sicre de Fontbrune, Flore, Marinho, Eduardo, Deschamps, Lydia, Di‐Lucca, Julie, Crickx, Beatrice, Descamps, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509882/
https://www.ncbi.nlm.nih.gov/pubmed/31110725
http://dx.doi.org/10.1002/ccr3.2137
_version_ 1783417339420606464
author Al Dhafiri, Mahdi
Sicre de Fontbrune, Flore
Marinho, Eduardo
Deschamps, Lydia
Di‐Lucca, Julie
Crickx, Beatrice
Descamps, Vincent
author_facet Al Dhafiri, Mahdi
Sicre de Fontbrune, Flore
Marinho, Eduardo
Deschamps, Lydia
Di‐Lucca, Julie
Crickx, Beatrice
Descamps, Vincent
author_sort Al Dhafiri, Mahdi
collection PubMed
description The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT.
format Online
Article
Text
id pubmed-6509882
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65098822019-05-20 Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type Al Dhafiri, Mahdi Sicre de Fontbrune, Flore Marinho, Eduardo Deschamps, Lydia Di‐Lucca, Julie Crickx, Beatrice Descamps, Vincent Clin Case Rep Case Reports The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT. John Wiley and Sons Inc. 2019-04-05 /pmc/articles/PMC6509882/ /pubmed/31110725 http://dx.doi.org/10.1002/ccr3.2137 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Al Dhafiri, Mahdi
Sicre de Fontbrune, Flore
Marinho, Eduardo
Deschamps, Lydia
Di‐Lucca, Julie
Crickx, Beatrice
Descamps, Vincent
Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
title Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
title_full Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
title_fullStr Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
title_full_unstemmed Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
title_short Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type
title_sort effectiveness of lenalidomide in relapsed primary cutaneous diffuse large b‐cell lymphoma, leg type
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509882/
https://www.ncbi.nlm.nih.gov/pubmed/31110725
http://dx.doi.org/10.1002/ccr3.2137
work_keys_str_mv AT aldhafirimahdi effectivenessoflenalidomideinrelapsedprimarycutaneousdiffuselargebcelllymphomalegtype
AT sicredefontbruneflore effectivenessoflenalidomideinrelapsedprimarycutaneousdiffuselargebcelllymphomalegtype
AT marinhoeduardo effectivenessoflenalidomideinrelapsedprimarycutaneousdiffuselargebcelllymphomalegtype
AT deschampslydia effectivenessoflenalidomideinrelapsedprimarycutaneousdiffuselargebcelllymphomalegtype
AT diluccajulie effectivenessoflenalidomideinrelapsedprimarycutaneousdiffuselargebcelllymphomalegtype
AT crickxbeatrice effectivenessoflenalidomideinrelapsedprimarycutaneousdiffuselargebcelllymphomalegtype
AT descampsvincent effectivenessoflenalidomideinrelapsedprimarycutaneousdiffuselargebcelllymphomalegtype

Ejemplares similares